A more recent cohort study adopted a propensity-score matching analysis of patients with T2D and cirrhosis demonstrated a lower rate of incident ascites (3.8% vs. 7.1%) and death (0.9% vs. 4.5%) in SGLT2i users compared to those who used dipeptidyl peptidase-4 inhibitors (DPP4i), although the difference in ascites rates was not statistically significant. Here, DPP4 is linked to Ascites.